Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
161 USD | +0.16% | -1.00% | +3.96% |
03:43pm | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
09/05 | Medincell: share price rises on resumption of trading | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.96% | 28TCr | |
+29.92% | 68TCr | |
+30.34% | 57TCr | |
-3.80% | 36TCr | |
+18.17% | 33TCr | |
+16.21% | 24TCr | |
+9.66% | 21TCr | |
-6.83% | 20TCr | |
+7.06% | 17TCr | |
-1.35% | 16TCr |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Raymond James Adjusts Price Target on AbbVie to $189 From $181, Maintains Outperform Rating